SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

3 Months Ended

Mar. 31, 2022

Accounting Policies [Abstract]

Schedule of Revenue by Payor Class

Revenue by payor class as a percentage of total net service revenue is as follows:

	For the Three-Month Periods Ended March 31,
	2022		2021
Home Health:
Medicare	41	%	41	%
Non-Medicare - Episodic-based	8	%	7	%
Non-Medicare - Non-episodic based	12	%	13	%
Hospice:
Medicare	34	%	34	%
Non-Medicare	2	%	2	%
Personal Care	3	%	3	%
High Acuity Care (1)	< 1%		—	%
	100	%	100	%

Schedule of Cash Cash Equivalents and Restricted Cash

The following table summarizes the balances related to our cash, cash equivalents and restricted cash (amounts in millions):

	As of March 31, 2022		As of December 31, 2021
Cash and cash equivalents	$	67.8	$	42.7
Restricted cash	3.1		3.1
Cash, cash equivalents and restricted cash	$	70.9	$	45.8

Schedule of Fair Value of Financial Instruments

The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):

	Fair Value at Reporting Date Using
Financial Instrument	Carrying Value as of March 31, 2022		Quoted Prices in Active Markets for Identical Items (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Long-term obligations	$	444.6	$	—	$	482.8	$	—

Schedule of Weighted-Average Shares Outstanding

The following table sets forth, for the periods indicated, shares used in our computation of weighted-average shares outstanding, which are used to calculate our basic and diluted net income attributable to Amedisys, Inc. common stockholders (amounts in thousands):

	For the Three- Month Periods Ended March 31,
	2022	2021
Weighted average number of shares outstanding - basic	32,555	32,780
Effect of dilutive securities:
Stock options	65	151
Non-vested stock and stock units	146	259
Weighted average number of shares outstanding - diluted	32,766	33,190
Anti-dilutive securities	188	42